
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp is poised for significant revenue growth, driven by its MACI product line, which is projected to experience a high-teens to low-twenties percentage growth in top-line sales for FY26, in line with market expectations. The anticipated volume compound annual growth rate (CAGR) of approximately 14.8% combined with an annual average selling price (ASP) increase of 300 to 500 basis points supports a sustainable revenue trajectory. Additionally, the updated guidance for fourth-quarter revenue reflects a notable 26% quarter-over-quarter increase, further solidifying a favorable outlook on Vericel's financial performance.
Bears say
Vericel Corporation has revised its revenue expectations for its MACI product downward by approximately 200 basis points for fiscal years 2026 and 2027, indicating a diminished growth outlook. The company faces several risks, including potential lower adoption rates of MACI Arthro, slower sales in the burn care segment, and challenges related to its sales force expansion, all of which could adversely impact overall revenue performance. If Vericel fails to meet top-line expectations in upcoming quarters, there is a consensus that the company's shares could decline to historically low valuation levels.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares